20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters (Q34006197)

30 July 2017

title

20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters (English)

1 reference

30 July 2017

0 references

2

Alexander M M Eggermont

1 reference

30 July 2017

Jan P Deroose

1

1 reference

30 July 2017

Albertus N van Geel

3

1 reference

30 July 2017

Johannes H W de Wilt

4

1 reference

30 July 2017

Jacobus W A Burger

5

1 reference

30 July 2017

Cornelis Verhoef

6

1 reference

30 July 2017

publication date

31 August 2011

1 reference

Annals of Surgical Oncology

30 July 2017

published in

1 reference

30 July 2017

volume

19

1 reference

30 July 2017

issue

2

1 reference

30 July 2017

page(s)

627-635

1 reference

Long-term outcome of isolated limb perfusion with tumour necrosis factor-α for patients with melanoma in-transit metastases.

30 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264869

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264869

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264869

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264869

Final version of 2009 AJCC melanoma staging and classification

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264869

Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264869

Surgery and radiotherapy in the treatment of cutaneous melanoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264869

Carbon dioxide laser ablation as first-line management of in-transit cutaneous malignant melanoma metastases

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264869

5 July 2018

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264869

Electrochemotherapy in treatment of tumours.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264869

TNF dose reduction in isolated limb perfusion.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264869

Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264869

One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264869

Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264869

Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264869

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264869

Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264869

Isolated limb perfusion with high-dose tumor necrosis factor-alpha for locally advanced extremity soft tissue sarcomas

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264869

A single centre's 10 year experience with isolated limb perfusion in the treatment of recurrent malignant melanoma of the limb.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264869

Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264869

Thirty-five years of isolated limb perfusion for melanoma: indications and results

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264869

Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264869

Regional therapy of melanoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264869

Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264869

Perspectives of Cytokine Treatment in Malignant Skin Tumors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264869

Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264869

Major amputation for advanced malignant melanoma.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264869

Prognostic scoring in patients with melanoma after adjuvant isolated limb perfusion.

5 July 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2030-7

Outcomes following isolated limb infusion for melanoma. A 14-year experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2030-7

TNF dose reduction and shortening of duration of isolated limb perfusion for locally advanced soft tissue sarcoma of the extremities is safe and effective in terms of long-term patient outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2030-7

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2030-7

Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264869

Hyperthermic Isolated Limb Perfusion With Low-Dose Tumor Necrosis Factor-α and Melphalan for Bulky In-Transit Melanoma Metastases

29 October 2018

1 reference

12 December 2020

Prognostic factors for survival after isolated limb perfusion for malignant melanoma

1 reference

12 December 2020

Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions

1 reference

12 December 2020

Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics

1 reference

12 December 2020

Low-dose tumour necrosis factor alpha and melphalan in hyperthermic isolated limb perfusion

1 reference

12 December 2020

Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma

1 reference

12 December 2020

Patient- and treatment-related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities

1 reference

12 December 2020

Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma

1 reference

12 December 2020

Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit

1 reference

12 December 2020

Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020

1 reference

12 December 2020

Long-Term Results of Melphalan-Based Isolated Limb Perfusion With or Without Low-Dose TNF for In-Transit Melanoma Metastases

1 reference

12 December 2020

Biologic behavior and treatment of intransit metastasis of melanoma

1 reference

12 December 2020

Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis

1 reference

12 December 2020

Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs

1 reference

12 December 2020

10.1245/S10434-011-2030-7

Identifiers

DOI

1 reference

Dimensions Publication ID

30 July 2017

0 references

1 reference

30 July 2017

1 reference